GTCR already owns the second largest medical device coatings manufacturer, Biocoat, and the FTC holds market monopoly ...

In the FTC’s first merger challenge of the new administration, the FTC voted 4-0 last week to challenge the proposed ...

SRDX stock falls more than 26% so far this year. However, this provides a unique opportunity to generate double-digit returns ...

Surmodics stock drops 4.76% in premarket trading following news that the FTC will challenge its proposed acquisition by GTCR.

The U.S. Federal Trade Commission (FTC) has moved to block the $627 million acquisition of cardiovascular devicemaker Surmodics by private equity firm GTCR over a potential plan to combine the ...

Surmodics stated today that it disagrees with the FTC’s decision and is focused on completing the merger, which it believes is pro-competitive and beneficial to stakeholders. The merger ...

The Federal Trade Commission announced it has sued to block GTCR BC Holdings’ acquisition of Surmodics (SRDX), alleging that the deal, which seeks to combine the two largest manufacturers of ...

The U.S. Federal Trade Commission has moved to block private-equity firm GTCR’s acquisition of Surmodics Inc., saying the deal would reduce competition in the medical device coatings industry.